Our activity is primarily based on the development and the production of new generation therapeutic molecules called Antibody-Drug Conjugates (ADCs). ADCs are innovative molecules for therapeutic use which not only dramatically increase the effectiveness of cytotoxic drugs currently used in many cancer treatment protocols, but also decrease significantly their adverse effects through their selective targeting of tumors.